Meds Apotek AB (STO:MEDS)
Sweden · Delayed Price · Currency is SEK | Market Cap | 429.02M -53.8% |
| Revenue (ttm) | 1.08B +16.4% |
| Net Income | 14.96M +455.6% |
| EPS | 0.81 +420.3% |
| Shares Out | 18.57M |
| PE Ratio | 28.68 |
| Forward PE | 15.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,024 |
| Open | 23.00 |
| Previous Close | 23.00 |
| Day's Range | 22.60 - 23.10 |
| 52-Week Range | 20.40 - 53.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 43.00 (+86.15%) |
| Earnings Date | Nov 6, 2026 |
About Meds Apotek AB
Meds Apotek AB operates as an online pharmacy that sells prescription and non-prescription medicines in Sweden. The company offers various products, including beauty products, dietary supplements, children's products, facial care, vitamins and supplements, oral care for animals, pet accessories, fur care, allergy medicine, sunscreen and body sunscreen, eye mask, sleep mask, earplugs, hearing aids, contact lenses, fitness products, electric toothbrush, heat tools for hair, food and drinks, and home & household products. The company was incorpora... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MEDS stock is "Strong Buy." The 12-month stock price target is kr 43.00, which is an increase of 86.15% from the latest price.
News
Meds Apotek AB Earnings Call Transcript: Q2 2026
Revenue grew 18% year-over-year to a record SEK 304 million, with EBIT up 38% and AOV at an all-time high. Gross margin declined to 27.1% due to strategic campaigns, but profitability improved. Guidance is reaffirmed, and the warehouse move is on track for Q3.
Meds Apotek AB Quarterly report: Q2 2026
Meds Apotek AB has published its Q2 2026 quarterly earnings report on July 21, 2026.
Meds Apotek AB Slides: Q2 2026
Meds Apotek AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Meds Apotek AB Earnings Call Transcript: Q1 2026
Q1 2026 delivered above-market growth, strong profitability, and a normalized gross margin, with Rx sales nearly doubling year-over-year. The upcoming move to a larger, more automated logistics center is expected to temporarily impact sales and EBIT but supports long-term growth targets.
Meds Apotek AB Quarterly report: Q1 2026
Meds Apotek AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
Meds Apotek AB Slides: Q1 2026
Meds Apotek AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Meds Apotek AB Earnings Call Transcript: Q4 2025
Achieved record sales and profitability, surpassing SEK 1 billion in revenue and 1 million customers, with strong Rx growth and a successful IPO. Gross margin faced Q4 pressure from competition, but cost control and a new warehouse position the company for future expansion.
Meds Apotek AB Quarterly report: Q4 2025
Meds Apotek AB has published its Q4 2025 quarterly earnings report on February 10, 2026.
Meds Apotek AB Slides: Q4 2025
Meds Apotek AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 10, 2026.
Meds Apotek AB Annual report: Q4 2025
Meds Apotek AB has published its Q4 2025 annual report on February 10, 2026.
Meds Apotek AB Annual report: Q4 2025
Meds Apotek AB has published its Q4 2025 annual report on February 10, 2026.
Meds Apotek AB Slides: ABGSC Investor Days
Meds Apotek AB has posted slides in relation to its latest quarterly earnings report, which was published on December 3, 2025.
Meds Apotek AB Earnings Call Transcript: Q3 2025
Q3 saw 22% sales growth, 2% EBIT, and strong cash flow, outpacing the market and achieving a milestone 1 million active customers. Prescription drug sales surged 52%, and the company remains on track for 20%-25% annual growth and 3%-5% EBIT margin by 2026.
Meds Apotek AB Quarterly report: Q3 2025
Meds Apotek AB has published its Q3 2025 quarterly earnings report on November 7, 2025.
Meds Apotek AB Slides: Q3 2025
Meds Apotek AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.